Compare Natera Inc. Common Stock (NTRA) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ProShares Ultra Semiconductors — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while ProShares Ultra Semiconductors trades at $82.21 (market cap $2.80B). The key difference: Natera Inc. Common Stock is far larger — about 20.4× ProShares Ultra Semiconductors's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ProShares Ultra Semiconductors for 30 Days on average.
| NTRA | USD | |
|---|---|---|
Market Cap | $57.03B | $2.80B |
Volume | 1,131,157 | 467,963 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $113.53 |
52-Week Low | $179.42 | $43.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
USD stock trades at $91.26 with a modest 0.26% daily gain, showing neutral momentum amid bearish technical signals. The company declared a $0.13 dividend for H2-2026, payable September 29, 2026. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support sits at $90 and resistance at $93.
Fundamental data remains limited with key ratios unavailable, requiring deeper financial review. The stock faces headwinds from bearish technical trends but maintains dividend distribution. Investment appeal hinges on upcoming financial disclosures and market sentiment shifts amid current neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
